Last reviewed · How we verify
clopidogrel and metoprolol
This combination drug uses clopidogrel to inhibit platelet aggregation and metoprolol to reduce heart rate and blood pressure, together reducing cardiovascular events.
This combination drug uses clopidogrel to inhibit platelet aggregation and metoprolol to reduce heart rate and blood pressure, together reducing cardiovascular events. Used for Secondary prevention after acute coronary syndrome or myocardial infarction, Reduction of cardiovascular events in patients with coronary artery disease.
At a glance
| Generic name | clopidogrel and metoprolol |
|---|---|
| Sponsor | University of Oxford |
| Drug class | Antiplatelet agent combined with beta-blocker |
| Target | P2Y12 receptor (clopidogrel); beta-1 adrenergic receptor (metoprolol) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Clopidogrel is a P2Y12 platelet receptor antagonist that prevents platelet activation and clot formation, while metoprolol is a beta-1 selective adrenergic antagonist that decreases heart rate, contractility, and blood pressure. Together, they provide dual antiplatelet and hemodynamic benefits for cardiovascular protection.
Approved indications
- Secondary prevention after acute coronary syndrome or myocardial infarction
- Reduction of cardiovascular events in patients with coronary artery disease
Common side effects
- Bleeding
- Bradycardia
- Fatigue
- Dyspnea
- Hypotension
Key clinical trials
- Effect of Enhanced External Counterpulsation (NA)
- Safety and Efficacy of Drug-Coated Balloon Angioplasty for the Treatment of Chronic Total Occlusions (NA)
- Efficacy and Safety of Wen Xin Granules for the Treatment of Unstable Angina Pectoris (PHASE4)
- The Success of Opening Concurrent CTO leSion to Improve Cardiac Function Trial in Patients With Multi-vessel Disease
- The Success of Opening Single CTO Lesions to Improve Myocardial Viability Study (SOS-comedy) (PHASE4)
- YouScript IMPACT Registry
- Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial Infarction (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- clopidogrel and metoprolol CI brief — competitive landscape report
- clopidogrel and metoprolol updates RSS · CI watch RSS
- University of Oxford portfolio CI